Certuity LLC Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Certuity LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,414 shares of the biopharmaceutical company’s stock after selling 108 shares during the quarter. Certuity LLC’s holdings in Regeneron Pharmaceuticals were worth $1,007,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mizuho Securities USA LLC raised its stake in Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares during the last quarter. Principal Financial Group Inc. raised its stake in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after buying an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. raised its stake in Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after buying an additional 3,231 shares during the last quarter. Golden State Equity Partners raised its stake in Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 1,272 shares during the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at $1,334,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of recent research reports. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $665.46 on Wednesday. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock has a 50-day moving average price of $714.37 and a 200 day moving average price of $906.38. The stock has a market capitalization of $73.13 billion, a P/E ratio of 17.38, a P/E/G ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company earned $11.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date is Thursday, February 20th.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.